医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mauna Kea Technologies Installs First Cellvizio System in India at Apollo Gleneagles Hospital Kolkata

2014年02月20日 AM02:40
このエントリーをはてなブックマークに追加


 

PARIS

Regulatory News :

Mauna Kea Technologies (Paris:MKEA) (Euronext: MKEA, FR0010609263), leader in the optical biopsy market, announced today it has installed its flagship Cellvizio system at the Apollo Gleneagles Hospital in Kolkata, a leading center of excellence in Gastroenterology in India, part of the Apollo Hospitals Group.

“This is great news for our patients”, said Dr Mahesh Goenka, Chief of Gastroenterology at Apollo Gleneagles, “Optical Biopsy with Cellvizio can now be used to improve patient management in several key gastroenterological indications and I am proud to be the first doctor in India to provide such advanced care. “

Apollo Hospitals has been the forerunner of integrated healthcare in Asia, as well as globally. Apollo Gleneagles Hospitals is a joint venture of Apollo Group of Hospitals, India and Parkway Health of Singapore. The Parkway Group is a leading healthcare group in Asia. A 510-bed multi-specialty tertiary care hospital – Apollo Gleneagles Hospitals Kolkata, is a perfect blend of technological excellence, complete infrastructure, competent care and heartfelt hospitality.

“Once again, Apollo Hospitals is at the forefront of patient care with the most advanced medical technologies available“, declared Dr Rupali Basu, CEO at Eastern region and Apollo Gleneagles Hospital. “The addition of Cellvizio to one of our leading centers of excellence in Gastroenterology is a great example of how we continue to break new grounds in India.”

Sacha Loiseau, CEO and founder of Mauna Kea Technologies, added: “We continue to make strong progress in our Asia-Pacific development and this first prestigious installation in India is another milestone in this high-growth region. We look forward to working with the Apollo Hospitals Group to improve patient care throughout the subcontinent.

About Apollo Hospitals and the Apollo Gleneagles Hospital Kolkata

Apollo Hospitals has been the forerunner of integrated healthcare in Asia, as well as globally. Today, the Group’s futuristic vision has ensured that it has been in a position of strength at every touch-point of the healthcare delivery chain. Its presence encompasses over 10,000 beds across 61 hospitals, more than 1,500 pharmacies, over 100 primary care and diagnostic clinics, 115 telemedicine units across nine countries, health insurance services, global projects consultancy, 15 academic institutions and a Research Foundation with a focus on global clinical trials, epidemiological studies, stem-cell and genetic research.
Apollo Gleneagles Hospitals is a joint venture of Apollo Group of Hospitals, India and Parkway Health of Singapore. The Parkway Group is a leading healthcare group in Asia. A 510-bed multispecialty tertiary care hospital – Apollo Gleneagles Hospitals Kolkata, is a perfect blend of technological excellence, complete infrastructure, competent care and heartfelt hospitality.
For more information Apollo Hospitals, visit: http://www.apollohospitals.com

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio’s ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic ducts and lungs and during fine needle aspiration procedures. Mauna Kea Technologies also obtained CE mark for a complete range of probes dedicated to urology.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com

CONTACT

Mauna Kea Technologies
Eric Cohen, Tel: +33
(0)1 70 08 09 70
Vice President Finance
investor-vpf@maunakeatech.com
or
France
and Europe

NEWCAP
Investor Relations &
Financial Communication
Florent Alba / Pierre Laurent, Tel: +33
(0)1 44 71 94 94
maunakea@newcap.fr

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent